ANKRD45 Inhibitors
ANKRD45 inhibitors comprise a spectrum of chemical entities that attenuate the functional activity of ANKRD45 by engaging with various cellular signaling pathways. For instance, the PI3K inhibitors LY 294002 and Wortmannin exert their effects by diminishing the PI3K/Akt signaling cascade, which, when ANKRD45 is a downstream participant, would lead to a reduction in ANKRD45's activity. The inhibition of MEK1/2 by U0126 and the blockade of ERK activation by PD98059 represent mechanisms that would also lead to a downstream decrease in ANKRD45 activity if it is regulated by the MAPK/ERK pathway. Similarly, the p38 MAPK inhibitor SB 203580 could indirectly inhibit ANKRD45 by dampening the cellular responses to stress and cytokines mediated by the p38 MAPK pathway. Rapamycin, targeting mTOR, and Gefitinib, inhibiting EGFR tyrosine kinase, both would result in a decrease in ANKRD45 activity if it is involved in mTOR or EGFR signaling pathways, respectively. These inhibitors operate by interfering with the signaling pathways essential for cell proliferation and survival, which in turn would diminish the functional role of ANKRD45 if it is implicated in these processes.
Further inhibitory effects arise from chemicals such as SP600125, which targets JNK signaling, potentially reducing ANKRD45's role if linked to JNK-mediated transcriptional regulation or apoptosis. The Src kinase inhibitor PP 2, by impeding Src kinase-mediated signal transduction, could indirectly lead to the diminution of ANKRD45 activity if ANKRD45 is modulated by Src kinase signaling. ZM-447439 and PD173074 both act by inhibiting kinases crucial for cell cycle progression and growth factor signaling; therefore, if ANKRD45's function is contingent upon these pathways, its activity would be indirectly diminished. Lastly, Y-27632 inhibits ROCK, affecting cytoskeleton dynamics and cell motility, pathways that could govern ANKRD45's activity. Collectively, these inhibitors provide a chemical toolkit capable of attenuating ANKRD45's activity through interference with specific signaling mechanisms, without direct binding or altering its expression levels.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). By inhibiting PI3K, this compound diminishes the PI3K/Akt pathway, which can lead to a reduction in the functional activity of ANKRD45 if ANKRD45 is a downstream effector in the PI3K/Akt signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 by SB203580 can lead to the reduction of cellular responses to stress and cytokines. If ANKRD45 is involved in p38 MAPK-mediated responses, its activity would be indirectly diminished by this chemical. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific mTOR inhibitor. By inhibiting mTOR, Rapamycin can affect the mTOR signaling pathway and lead to a decrease in protein synthesis and cell proliferation. If ANKRD45 function is linked to mTOR pathway outputs, its activity would be diminished with Rapamycin. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a steroidal metabolite that acts as a potent PI3K inhibitor. Like LY294002, Wortmannin's inhibition of PI3K activity leads to a decrease in Akt pathway signaling, potentially diminishing the activity of ANKRD45 if it's involved in this signaling cascade. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which inhibits the activation of MAPK/ERK. By preventing the activation of ERK, PD 98059 could indirectly diminish the activity of ANKRD45 if ANKRD45 is modulated by the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which modulates transcription factors and apoptosis. If ANKRD45 is part of the JNK signaling pathway, its functional activity would be indirectly diminished by SP600125's inhibition of JNK. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP 2 is an Src family kinase inhibitor. It impedes Src kinase-mediated signal transduction pathways. If ANKRD45 activity is modulated through Src kinase signaling, then PP 2 would indirectly lead to the diminishment of ANKRD45 activity by blocking Src kinase functions. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It blocks EGFR signaling, which can impact a variety of downstream pathways, including cell proliferation and survival. If ANKRD45 is part of the EGFR pathway, its activity would be diminished by Gefitinib. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is a selective inhibitor of Aurora kinase activity, which is crucial for cell cycle progression. If ANKRD45 is involved in cell cycle control and is regulated by Aurora kinases, its function would be indirectly diminished by ZM-447439. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is a specific inhibitor of the fibroblast growth factor receptor (FGFR) tyrosine kinase. If ANKRD45 is regulated by FGFR signaling pathways, inhibition by PD173074 would lead to a decrease in the activity of ANKRD45. | ||||||